'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Ipca Laboratories has increased 15.78% to Rs 2354.9 crore. Operating profit margin has jumped from 17.73% to 18.75%, leading to 22.44% rise in operating profit to Rs 441.48 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 28.87% to 25.18%. Purchase of finished goods cost fell from 6.83% to 6.58%. Employee cost increased from 20.19% to 21.80%. Other expenses rose from 27.02% to 27.57%.
Other income fell 31.88% to Rs 26.26 crore. PBIDT rose 17.20% to Rs 467.74 crore. Provision for interest fell 48.87% to Rs 22.56 crore. Loan funds declined from Rs 1,987.46 crore as of 30 September 2023 to Rs 1,202.18 crore as of 30 September 2024. Inventories rose to Rs 2,518.21...
Pleaselogin & subscribe to view the full report.
More Reports
|
|